Hamilton Thorne to Present at BioFinance 2010 Investor Conference

TSX VENTURE: HTL

TORONTO, April 6 /CNW/ - Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of advanced laser systems and instruments for the stem cell research and fertility clinic markets, today announced that Meg Spencer, Chairman and CEO of Hamilton Thorne is scheduled to present an overview of the Company's operations at the 2010 BioFinance Investor Conference, held at the Toronto Marriott Eaton Centre Hotel in Toronto. The presentation is scheduled from 10:00 am to 10:30 am (Eastern Time) on April 7, 2010 in the Trinity I Room. Interested parties can access an archived copy of the presentation slides the morning of the Conference by visiting Hamilton Thorne's website at www.hamiltonthorne.com.

About Hamilton Thorne Ltd.

Hamilton Thorne's advanced laser systems and instruments are rapidly emerging as the dominant products to facilitate precise procedures in the stem cell research and fertility clinic markets. Hamilton Thorne's lead products, the ZILOS-tk and XYClone laser systems, attach to standard inverted microscopes and operate as robotic micro-surgeons, significantly reducing time and increasing efficiency in key in-vitro fertilization, stem cell, embryo, reproductive toxicology and living cell procedures.

Hamilton Thorne's growing customer base includes pharmaceutical companies, biotechnology companies, fertility clinics, university research centers and other commercial and academic research establishments worldwide. Current customers include world-leading research labs such as Harvard University, MIT, Yale, DuPont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, Oxford University and Cambridge.

About BioFinance 2010

BioFinance 2010 is the leading investor conference in Canada for the life sciences industry. This three-day event brings together key industry players interested in investment opportunities and issues affecting companies in the life sciences sector. Presenting companies will span a range of industries including: biologics, medical devices, drug delivery, vaccines, diagnostics, bio-energy, green technologies, bio materials, industrial biotech, and research services.

Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the company with the Canadian securities regulators, which filings are available at www.sedar.com.

For further information: Hamilton Thorne Ltd., David Wolf, President, Phone: [phone], E-mail: [email protected]; Investor Relations, Ross Marshall, The Equicom Group Inc., Phone: [phone] (Ext. 238), E-mail: [email protected]